Loading stock data…
CTKB
$4.62+0.06 (+1.32%)
Market ClosedLast close May 1
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cytek Biosciences, Inc. in the Healthcare sector is trading at $4.62. The stock is currently 25% below its 52-week high of $6.18, remaining 4.1% above its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why CTKB maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.62
Potential Upside
5%
Whystock Fair Value$4.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$597.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.87%
Volume
Today's trading volume
415,408
Recent News
AbCellera Biologics Among 3 Promising Penny Stocks
In the last week, the market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings forecast to grow by 16% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when built on solid financials. In this article, we explore three penny stocks that combine balance sheet strength with potential for outsized gains, providing investors a chance to discover hidden...
Cytek Biosciences (CTKB) Inspiring Confidence With Aurora CS System Updates
Cytek Biosciences Inc. (NASDAQ:CTKB) is one of the 8 Best Life Sciences Penny Stocks to Buy. As of the April 8 closing, the consensus sentiment around Cytek Biosciences Inc. (NASDAQ:CTKB) remained moderately bullish. With 1 Buy rating and 1 Hold rating, the stock has a projected median 1-year price target of $6.25, resulting in an […]
Nautilus Biotechnology And 2 Other Compelling Penny Stocks For Your Watchlist
Over the last 7 days, the U.S. market has dropped by 2.3%, though it has shown a robust increase of 13% over the past year, with earnings projected to grow by 16% annually in the coming years. In such fluctuating conditions, identifying stocks with strong fundamentals and solid balance sheets can be crucial for investors seeking growth opportunities at lower price points. Penny stocks, often representing smaller or newer companies, continue to present underappreciated potential for growth and...
Cytek Biosciences Highlights Aurora Evo, Recurring Revenue Growth and 2026 Outlook at TD Cowen Conference
Cytek Biosciences (NASDAQ:CTKB) outlined its recent product launches, geographic diversification, and expectations for 2026 during a presentation and fireside chat at TD Cowen’s 42nd annual healthcare conference. CEO and Chairman Wenbin Jiang and CFO William McCombe discussed the company’s installed
How The Cytek Biosciences (CTKB) Story Is Shifting With New Targets And 2026 Guidance
Cytek Biosciences has seen its fair value estimate adjusted from US$5.75 to US$6.00, placing the stock in a slightly higher US$5 to US$6 price target framework. Analysts attribute this shift to a more constructive stance on the name, using clearer multi year models and a potential recovery in diagnostic tools to outline where Cytek could sit within the group. As you read on, you will see how these evolving targets and narratives might influence the way you track the story from here. Analyst...